Ray Dalio’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$956K Buy
+33,517
New +$1.14M ﹤0.01% 794
2024
Q4
Sell
-19,685
Closed -$552K 699
2024
Q3
$552K Sell
19,685
-20,632
-51% -$509K ﹤0.01% 679
2024
Q2
$918K Sell
40,317
-5,692
-12% -$131K ﹤0.01% 677
2024
Q1
$1.4M Buy
46,009
+25,579
+125% +$857K 0.01% 540
2023
Q4
$729K Sell
20,430
-1,517
-7% -$56.4K ﹤0.01% 673
2023
Q3
$961K Sell
21,947
-38,723
-64% -$1.89M 0.01% 612
2023
Q2
$2.99M Sell
60,670
-4,676
-7% -$216K 0.02% 407
2023
Q1
$2.71M Buy
65,346
+11,732
+22% +$487K 0.02% 416
2022
Q4
$2.38M Sell
53,614
-18,248
-25% -$762K 0.01% 501
2022
Q3
$2.81M Buy
71,862
+93
+0.1% +$4.25K 0.01% 490
2022
Q2
$2.93M Buy
71,769
+6,983
+11% +$331K 0.01% 605
2022
Q1
$4.25M Buy
64,786
+15,930
+33% +$1.03M 0.02% 509
2021
Q4
$3.4M Buy
48,856
+6,926
+17% +$503K 0.02% 380
2021
Q3
$2.92M Sell
41,930
-1,494
-3% -$115K 0.02% 374
2021
Q2
$3.44M Buy
+43,424
New +$3.16M 0.02% 401

Other funds holding ATRC

Ray Dalio's ATRC Position: Q1 2026 in Review

Ray Dalio opened a new position in AtriCure (ATRC) in Q1 2026: 33,517 shares worth $956K. The stake represents ﹤0.01% of the portfolio and ranks #794 among its holdings. This is a return to the name: Ray Dalio previously reported a position in ATRC as recently as Q3 2024.

Ray Dalio first reported a position in ATRC in Q2 2021 and has held it in 15 quarters since. The position peaked at $4.25M in Q1 2022. 223 funds tracked by Wall St. Rank hold ATRC as of Q1 2026.

  • Ray Dalio held 33,517 shares of AtriCure worth $956K as of Q1 2026.
  • AtriCure was a new Ray Dalio position in Q1 2026.
  • AtriCure made up ﹤0.01% of Ray Dalio's portfolio in Q1 2026, its #794 holding.
  • Ray Dalio first reported a position in AtriCure in Q2 2021 and has held it in 15 quarters since.
  • Ray Dalio's AtriCure position peaked at $4.25M in Q1 2022.
  • 223 funds tracked by Wall St. Rank held AtriCure as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.